CIK 0001714899
- Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 463872213
- Phone
- +1 650-866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 4 Open-market sale Director sold 3,339 shares at $20.81 ($69,485)
- 4 Grant or award President and CEO acquired 54,180 shares (grant or award)
- 4 Grant or award COFO and Secretary acquired 54,180 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 54,180 shares (grant or award)
- 4 Planned sale Director sold 30,000 shares at $20.25 ($607,500)
- 4 Planned sale Director sold 3,080 shares at $20.91 ($64,403)
- 4 Option exercise COFO and Secretary acquired 6,708 shares (option exercise)
- 4 Option exercise Chief Medical Officer acquired 17,845 shares (option exercise)
- 4 Option exercise COFO and Secretary acquired 20,516 shares (option exercise)
- 4 Planned sale Director sold 59,441 shares at an average $32.51 ($1,932,665)
- 4 Planned sale COFO and Secretary sold 15,558 shares at an average $29.91 ($465,286)
- 4 Planned sale Director sold 1,020 shares at $30.00 ($30,600)
- 4 Planned sale Director sold 3,080 shares at $27.07 ($83,376)
- 4 Planned sale President and CEO sold 40,000 shares at $27.69 ($1,107,600)
- 4 Planned sale Director sold 30,000 shares at $29.03 ($870,900)
- 4 Planned sale Director sold 1,020 shares at $30.00 ($30,600)
- 4 Planned sale Director sold 3,080 shares at an average $25.00 ($77,007)
- 4 Open-market sale President and CEO sold 2,260 shares at $23.79 ($53,765)
- 4 Open-market sale Director sold 1,727 shares at $23.79 ($41,085)
- 4 Planned sale COFO and Secretary sold 8,353 shares at an average $23.99 ($200,401)
Page 3 of 22 · 436 filings